uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
uniQure BV (QURE) PT Raised to $72 at B.Riley/FBR
November 15, 2018 9:58 AM ESTB.Riley/FBR analyst Madhu Kumar raised the price target on uniQure BV (NASDAQ: QURE) to $72.00 (from $50.00) while maintaining a Buy rating.
... MoreuniQure BV (QURE) PT Raised to $65 at Cantor Fitzgerald
November 15, 2018 9:36 AM ESTCantor Fitzgerald analyst Elemer Piros raised the price target on uniQure BV (NASDAQ: QURE) to $65.00 (from $58.00) while maintaining a Overweight rating.
Piros commented, "This morning, uniQure announced initial top-line data from the Phase 2b dose-confirmation study of AMT-061 for the treatment of... More
uniQure BV (QURE) PT Raised to 'Street High' $76 at Leerink Partners
November 15, 2018 8:56 AM ESTLeerink Partners analyst Joseph Schwartz raised the price target on uniQure BV (NASDAQ: QURE) to a 'Street High' $76.00 (from $61.00) while maintaining an Outperform rating following AMT-061 data.
... MoreuniQure (QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
November 15, 2018 7:20 AM ESTuniQure (NASDAQ: QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
... More